Business
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the completed Phase 1/2 MARINA® trial of delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1 (DM1) will be published in the February 19 issue of The New England Journal of Medicine (NEJM). The manuscript is titled "An Antibody Oligonucleotide Con
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"Treatment demonstrated improvements in multiple measures including myotonia, muscle function and strength, mobility and patient-reported outcomes","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"Del-desiran showed acceptable safety and tolerability with most adverse events mild or moderate","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the completed Phase 1/2 MARINA® trial of delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1 (DM1) will be published in the February 19 issue of The New England Journal of Medicine (NEJM). The manuscript is titled "An Antibody Oligonucleotide Conjugate for Myotonic Dystrophy Type 1."","length":594,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Avidity Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Avidity Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":188,"url":"https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CUqGwDlJgRQuW4SSqvStJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79","width":400,"height":188}},"href":"https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"DM1 is an underrecognized, progressive and often fatal neuromuscular disease with no disease modifying therapies. Del-desiran is an investigational treatment designed to address the underlying genetic root cause of DM1 by reducing total levels of the toxic, DMPK (myotonic dystrophy protein kinase) mRNA. The accumulation of these toxic mRNA sequester key RNA-regulatory proteins that subsequently lead to missplicing of several downstream genes, resulting in the dive...